Skip to main content

Advertisement

SpringerLink
Log in

The GHSG Approach to Treating Hodgkin’s Lymphoma

  • B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Hodgkin’s lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients can be cured long term. In refractory or relapsed HL, intensified treatment including high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is associated with progression-free survival (PFS) of 50 %. Evaluation of novel drugs in multiple relapsed or refractory cases, better treatment options for elderly patients and reducing treatment-related side effects are the main focus of current research. Recent clinical developments and future approaches in the treatment of HL will be discussed in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2011. 01.04.2014 2014. http://seer.cancer.gov/csr/1975_2011/ (accessed 30.12.2014 2014).

  2. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995;332(7):413–8.

    Article  CAS  PubMed  Google Scholar 

  3. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathol. 1987;129(1):86–91.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin’s lymphoma and other lymphoid neoplasms. Int J Cancer Jc Ancer. 1999;83(4):481–5.

    Article  CAS  Google Scholar 

  5. Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma. 2009;9(3):206–16.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol : Off J Am Soc Clin Oncol. 2014;32(27):3059–68.

    Article  Google Scholar 

  7. Engert A, Ballova V, Haverkamp H, et al. Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(22):5052–60.

    Article  Google Scholar 

  8. Stark GL, Wood KM, Jack F, et al. Hodgkin’s disease in the elderly: a population-based study. Br J Haematol. 2002;119(2):432–40.

    Article  PubMed  Google Scholar 

  9. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.

    Article  CAS  PubMed  Google Scholar 

  10. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531–3.

    Article  PubMed  Google Scholar 

  11. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29(31):4096–104.

    Article  CAS  Google Scholar 

  12. Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–9.

    Article  CAS  PubMed  Google Scholar 

  13. Sasse S, Klimm B, Gorgen H, et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin’s lymphoma. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2012;23(11):2953–9.

    Article  CAS  Google Scholar 

  14. Heutte N, Flechtner HH, Mounier N, et al. Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10(12):1160–70.

    Article  PubMed  Google Scholar 

  15. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol : Off J Am Soc Clin Oncol. 2003;21(18):3431–9.

    Article  Google Scholar 

  16. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer. 1997;33(6):848–53.

    Article  CAS  PubMed  Google Scholar 

  17. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–27.

    Article  CAS  PubMed  Google Scholar 

  18. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(23):3495–502.

    Article  CAS  Google Scholar 

  19. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol : Off J Am Soc Clin Oncol. 2004;22(14):2835–41.

    Article  Google Scholar 

  20. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.

    Article  CAS  PubMed  Google Scholar 

  21. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399–408.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical hodgkin lymphoma: analysis of the national cancer data base. J Clin Oncol : Off J Am Soc Clin Oncol 2015. This analysis evaluated impact of radiotherapy in early stage HL and demonstrated better OS for CMT in comparison to chemotherapy alone.

  23. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol : J Eur Soc Ther Radiol Oncol. 2006;79(3):270–7.

    Article  Google Scholar 

  24. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(32):5170–4.

    Article  Google Scholar 

  25. Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2014;32(12):1188–94.

    Article  Google Scholar 

  26. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607.

    Article  CAS  PubMed  Google Scholar 

  27. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial [abstract]. Haematologica. 2010;95 Suppl 2:473.

    Google Scholar 

  28. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. The Lancet 2014. This trial demonstrated that single drugs cannot be omitted from ABVD without loss in disease control and hence confirmed 2x ABVD followed by 20Gy as standard therapy in early favorable HL.

  29. Park SI, Richards KL, Olajide O, et al. A phase 2 trial of induction chemotherapy with ABVD followed by brentuximab vedotin consolidation in patients with previously untreated non-bulky stage I or II Hodgkin lymphoma; 2014.

  30. Zinzani PL, Luminari S, Merli F, et al. Brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma. A pilot phase II study; 2014.

  31. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol : Off J Am Soc Clin Oncol. 2006;24(19):3128–35.

    Article  Google Scholar 

  32. Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2013;24(12):3070–6.

    Article  CAS  Google Scholar 

  33. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28(27):4199–206.

    Article  Google Scholar 

  34. Thomas J, Ferme C, Noordijk E. Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma. Haematologica 2007; 92(suppl. 1).

  35. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 1996;7 Suppl 4:95–8.

    Article  Google Scholar 

  36. Wasserman TH, Petroni GR, Millard FE, et al. Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: a phase II Cancer and Leukemia Group B Study (9051). Cancer. 1999;86(8):1590–5.

    Article  CAS  PubMed  Google Scholar 

  37. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2012;30(9):907–13.

    Article  Google Scholar 

  38. Sasse S, von Tresckow B, Plütschow A, et al. Impact of dose intensification on the outcome in early-stage unfavorable HL: 7-year follow-up analysis of the GHSG HD14 trial (abstract). Haematologica 2013; 98(13).

  39. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(6):684–91.

    Article  Google Scholar 

  40. Hay AE, Klimm B, Chen BE, et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2013;24(12):3065–9.

    Article  CAS  Google Scholar 

  41. Diehl V, Mauch P, Harris NL. In: Devita VT, Hellmann S, Rosenberg S, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2001.

  42. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol : Off J Am Soc Clin Oncol. 1986;4(9):1295–306.

    CAS  Google Scholar 

  43. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986;104(6):739–46.

    Article  CAS  PubMed  Google Scholar 

  44. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol : Off J Am Soc Clin Oncol. 1987;5(1):27–37.

    CAS  Google Scholar 

  45. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–84.

    Article  CAS  PubMed  Google Scholar 

  46. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol : Off J Am Soc Clin Oncol. 1996;14(5):1421–30.

    CAS  Google Scholar 

  47. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2003;21(4):607–14.

    Article  CAS  Google Scholar 

  48. Stefan DC, Stones D. How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma. 2009;50(2):196–9.

    Article  PubMed  Google Scholar 

  49. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med. 2002;346(18):1417–8.

    Article  PubMed  Google Scholar 

  50. Radford JA, Crowther D, Rohatiner AZ, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin’s disease. J Clin Oncol : Off J Am Soc Clin Oncol. 1995;13(9):2379–85.

    CAS  Google Scholar 

  51. Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol : Off J Am Soc Clin Oncol. 2002;20(13):2988–94.

    Article  CAS  Google Scholar 

  52. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(36):9208–18.

    Article  CAS  Google Scholar 

  53. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2002;20(3):630–7.

    Article  Google Scholar 

  54. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(36):9198–207.

    Article  CAS  Google Scholar 

  55. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol : Off J Am Soc Clin Oncol. 2009;27(32):5390–6.

    Article  Google Scholar 

  56. Hasenclever D, Brosteanu O, Gerike T, Loeffler M. Modelling of chemotherapy: the effective dose approach. Ann Hematol. 2001;80 Suppl 3:B89–94.

    CAS  PubMed  Google Scholar 

  57. Diehl V. Dose-escalation study for the treatment of Hodgkin’s disease. The German Hodgkin Study Group (GHSG). Ann Hematol. 1993;66(3):139–40.

    Article  CAS  PubMed  Google Scholar 

  58. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–95.

    Article  CAS  PubMed  Google Scholar 

  59. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol : Off J Am Soc Clin Oncol. 2009;27(27):4548–54.

    Article  Google Scholar 

  60. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379(9828): 1791–9. Results of this trial allowed reduction from eight to six cycles of BEACOPP escalated and implemented PET-adapted radiotherapy in advanced stage HL

  61. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112(10):3989–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2009;27(5):805–11.

    Article  Google Scholar 

  63. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–12.

    Article  CAS  PubMed  Google Scholar 

  64. Borchmann P, Diehl V, Engert A. ABVD versus BEACOPP for Hodgkin’s lymphoma. N Engl J Med. 2011;365(16):1545–6. author reply 6.

  65. Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles >/=4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial dagger. Ann Oncol : Off J Eur Soc Oncol / ESMO. 2014;25(8):1622–8.

    Article  Google Scholar 

  66. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14(10): 943–52. This meta-analysis confirmed the superiority of BEACOPP escalated over ABVD for PFS and OS in advanced stage HL.

  67. Eichenauer DA, Plütschow A, Kreissl S, et al. Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study; 2013.

  68. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56. This phase I trial demonstrated safety, feasibility and efficacy of AVD in combination with Brentuximab vedotin in first line therapy of early stage HL.

    Article  CAS  PubMed  Google Scholar 

  69. Wongso D, Fuchs M, Plutschow A, et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin Study Group. J Clin Oncol. 2013;31(22):2819–24.

    Article  PubMed  Google Scholar 

  70. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol. 2004;124(5):645–52.

    Article  PubMed  Google Scholar 

  71. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2002;20(1):221–30.

    Article  PubMed  Google Scholar 

  72. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol : Off J Eur Soc Oncol / ESMO. 2002;13(10):1628–35.

    Article  CAS  Google Scholar 

  75. Magagnoli M, Spina M, Balzarotti M, et al. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin’s lymphoma patients. Bone Marrow Transplant. 2007;40(11):1019–25.

    Article  CAS  PubMed  Google Scholar 

  76. Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010;28(34):5074–80.

    Article  PubMed  Google Scholar 

  77. Chen RW, Palmer J, Martin P, et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT; 2014.

  78. Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(32):5240–7.

    Article  Google Scholar 

  79. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(36):5980–7.

    Article  Google Scholar 

  80. Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073–9.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Moskowitz CH, Nadamanee A, Masszi T, et al. The Aethera trial: results of a randomized, double-blind, placebo-controlled phase 3 study of brentuximab vedotin in the treatment of patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma; 2014.

  82. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2):310–7.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.

    Article  CAS  PubMed  Google Scholar 

  85. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. This trial led to FDA approval for Brentuximab vedotin in relapsed or refractory HL.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory hodgkin’s lymphoma. New Engl J Med 2014. This trial demonstrated efficacy and tolerability of Nivolumab in relapsed or refractory HL.

  87. Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013); 2014.

  88. Enblad G, Glimelius B, Sundstrom C. Treatment outcome in Hodgkin’s disease in patients above the age of 60: a population-based study. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 1991;2(4):297–302.

    CAS  Google Scholar 

  89. Weekes CD, Vose JM, Lynch JC, et al. Hodgkin’s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol : Off J Am Soc Clin Oncol. 2002;20(4):1087–93.

    Article  CAS  Google Scholar 

  90. Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(12):1522–9.

    Article  Google Scholar 

  91. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2005;16(1):124–31.

    Article  CAS  Google Scholar 

  92. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692–5.

    Article  CAS  PubMed  Google Scholar 

  93. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Böll B, Behringer K, Görgen H, et al. Doxorubicin, vinblastine and dacarbazine with or without bleomycin for older patients with early stage favorable hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials; 2014.

  95. Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118(24):6292–8.

    Article  PubMed  Google Scholar 

  96. Halbsguth TV, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116(12):2026–32.

    Article  CAS  PubMed  Google Scholar 

  97. Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma. 2007;48(3):570–6.

    Article  CAS  PubMed  Google Scholar 

  98. Boll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(35):4431–7.

    Article  Google Scholar 

  99. Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2006: 266–72.

  100. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on lymphocyte-predominant Hodgkin’s disease. J Clin Oncol : Off J Am Soc Clin Oncol. 1999;17(3):776–83.

    CAS  Google Scholar 

  101. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(3):434–9.

    Article  Google Scholar 

  102. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2005;16(10):1683–7.

    Article  CAS  Google Scholar 

  103. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28(1):136–41.

    Article  Google Scholar 

  104. Eichenauer DA, Pluetschow A, Fuchs M, et al. Treatment of stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an analysis from the German Hodgkin Study Group (GHSG); 2014.

  105. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118(16):4363–5.

    Article  CAS  PubMed  Google Scholar 

  106. Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP. ASH Annual Meeting Abstracts. 2010;116(21):2812.

    Google Scholar 

  107. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109–11.

    Article  CAS  PubMed  Google Scholar 

  108. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101(11):4285–9.

    Article  CAS  PubMed  Google Scholar 

  109. Karuturi M, Hosing C, Fanale M, et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2013;19(6):991–4.

    Article  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Paul Bröckelmann reports nonfinancial support from Millennium/Takeda.

Prof. Dr. Andreas Engert reports grants and personal fees from Millennium/Takeda, grants and personal fees from Affimed, and personal fees from Bristol-Myers Squibb.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. German Hodgkin Study Group (GHSG) and Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany

    Paul J. Bröckelmann & Andreas Engert

Authors
  1. Paul J. Bröckelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Engert.

Additional information

This article is part of the Topical Collection on B-cell NHL, T-cell NHL and Hodgkin Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bröckelmann, P.J., Engert, A. The GHSG Approach to Treating Hodgkin’s Lymphoma. Curr Hematol Malig Rep 10, 256–265 (2015). https://doi.org/10.1007/s11899-015-0262-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-015-0262-5

Keywords

Search

Navigation